U.S. Markets open in 7 hrs 17 mins
  • S&P Futures

    4,339.25
    +21.50 (+0.50%)
     
  • Dow Futures

    34,168.00
    +125.00 (+0.37%)
     
  • Nasdaq Futures

    14,121.75
    +135.00 (+0.97%)
     
  • Russell 2000 Futures

    1,930.50
    +2.20 (+0.11%)
     
  • Crude Oil

    87.19
    +0.58 (+0.67%)
     
  • Gold

    1,795.30
    +2.20 (+0.12%)
     
  • Silver

    22.71
    +0.03 (+0.15%)
     
  • EUR/USD

    1.1143
    -0.0004 (-0.0334%)
     
  • 10-Yr Bond

    1.8070
    0.0000 (0.00%)
     
  • Vix

    30.49
    -1.47 (-4.60%)
     
  • GBP/USD

    1.3395
    +0.0014 (+0.1045%)
     
  • USD/JPY

    115.5760
    +0.2740 (+0.2376%)
     
  • BTC-USD

    37,033.09
    +935.89 (+2.59%)
     
  • CMC Crypto 200

    839.73
    +20.23 (+2.47%)
     
  • FTSE 100

    7,554.31
    +84.53 (+1.13%)
     
  • Nikkei 225

    26,717.34
    +547.04 (+2.09%)
     

Aptevo Therapeutics Stock More Than Doubles After Leukemia Study News

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • APVO

By Sam Boughedda

Investing.com — Aptevo Therapeutics Inc (NASDAQ:APVO) shares have surged over 129% to $14.88 Tuesday after it reported that a patient in its phase 1b expansion trial evaluating its treatment for acute myeloid leukemia had a complete remission.

The biotechnology explained that the high-risk AML patient achieved complete remission after one cycle of therapy. In addition, there was no evidence of overt toxicity, Aptevo said.

The overall aim of the study is to determine if the treatment can enhance the quality of remission in high-risk AML patients.

The company said it "believes that APVO436 has the potential to help AML patients achieve complete remissions without measurable residual disease (MRD) and thereby reduce their risk of leukemic relapses."

Related Articles

Aptevo Therapeutics Stock More Than Doubles After Leukemia Study News

Shares retreat as traders see higher rates; Turkish lira nosedives

With U.S. inventories tight, 'Black Friday' drags through November